Skip to main content
Fig. 3 | Reproductive Biology and Endocrinology

Fig. 3

From: Effectiveness of NLRP3 Inhibitor as a Non-Hormonal Treatment for ovarian endometriosis

Fig. 3

Effects of MCC950 on ESCs and CSCs. (A) ESCs and CSCs were treated with MCC950 (0.01, 1, and 100 μM) and the surviving fraction was measured after a 24 h incubation. Data are shown as mean ± SEM of triplicate samples obtained from patients; ESCs (n = 4) and CSCs (n = 4). (B) Immunofluorescence analysis of the expression of NLRP3 and IL-1β in ESCs and CSCs. Representative immunostaining images (upper) and quantitative analysis (lower) of the ratio of NLRP3/IL-1β co-labeled cells to total cells after incubating with or without MCC950 (100 μM) for 16 h. Data are shown as mean ± SEM obtained from primary cell cultures; ESCs (n = 3) and CSCs (n = 3); Scale bar: 50 μm. Ratio of IL-1β (C) and IL-18 (D) levels in CSC culture supernatant from untreated and MCC950-treated (100 μM) cultures after 16 h. Data are shown as mean ± SEM of duplicates obtained from primary cell cultures; (C) ESCs (n = 7) and CSCs (n = 8), (D) ESCs (n = 7) and CSCs (n = 9). Statistical significances were calculated using one-way ANOVA followed by Dunnett’s multiple comparison test (A and B) and Student’s t-test (C and D). *P < 0.05 and **P < 0.01; ESCs eutopic endometrium-derived stromal cells, with endometriosis, CSCs ovarian endometriosis (chocolate cyst)-derived stromal cells

Back to article page